Tamsulosin kullanımına bağlı olarak gelişen intraoperatif floppy iris sendromu( ifis ): Ürolojik yaklaşım

İntraoperatif floppy iris sendromu(İFİS) benign prostat hiperplazisi nedeniyle tamsulosin kullanan ve katarakt cerrahisi uygulanan hastalarda tanımlanmış yeni bir sendromdur. Bu sendrom gevşek iris, kornea kesi giriş yerlerinden sürekli prolobe olmaya eğilimi olan iris ve operasyon sırasında ani ve progresif pupiller miyozis gelişmesi ile karakterizedir. Bütün bu durumlar intraoperatif komplikasyon gelişme riskini arttırmaktadır. Cerrahi sırasında oluşabilecek komplikasyonları azaltmak için hastanın halen yada geçmişte alfa-1 bloker kullanıp kullanmadığı göz hastalıkları uzmanı tarafından bilinmelidir. Üroloji uzmanı alfa-1 bloker yazma alışkanlığını değiştirmemeli. Bununla birlikte, bir selektif alfa-1 bloker reçetelenirken hastada katarakt olup olmadığı ve cerrahi planlanlanıp planlanmadığı göz önünde bulundurmalıdır.

Intraoperatıve floppy iris syndrome (ifis) due to tamsulosin use : Urological approach

Intraoperative floppy iris syndrome(IFIS)is new syndrome which has been recently described in patients undergoing cataract surgery and taking tamsulosin for managing benign prostate hyperplasia(BPH). This syndrome is characterized by flaccid iris stroma, a propensity of the iris to prolapse toward the corneal incision, and progressive miosis, all conditions that potentially increase the risk of intraoperative complications. Current or past use of alpha-1 blockers in patients undergoing cataract surgery should be known by oftalmologist to reduce the risk of complications during surgery. Urologists should not change the prsecribing habits of alpha-1 blockers. However, they considering prescribing a selective alpha-blocker should ask the patient if they have known cataracts and if surgery is planned.

PDF

___

1) Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005; 31:664-673.
2) Chadha V, Borooah S, Tey A, Styles C, Singh J. Floppy iris behaviour during cataract surgery: associations and variations. Br J Ophthalmol 2007; 91:40-42.
3) Blouin MC, Blouin J, Perreault S, Lapointe A, Dragomir A. Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin. J Cataract Refract Surg 2007; 33:1227-1234.
4) Oshika T, Ohashi Y, Inamura M, Ohki K, Okamoto S, Koyama T, et al. Incidence of intraoperative floppy Iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist. Am J Ophthalmol 2007; 143:150-151.
5) Andersson KE. Alpha-adrenoreceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoreceptor antagonists. World J Urol 2002; 19:390-396.
6) Schwinn DA, Afshari NA. Alpha(1)-Adrenergic receptor antagonists and the iris: new mechanistic insights into floppy iris syndrome. Surv Ophthalmol 2006; 51:501-512.
7) Chang DF, Osler RH, Wang L, Koch DD. Prospective multicenter evaluation of cataract surgery in patients taking tamsulosin(Flomax). Ophthalmology 2007; 114:957-964.
8) Gurbaxani A, Packard R. Intracameral phenylephrine to prevent floppy iris syndrome during cataract surgery in patients on tamsulosin. Eye 2007; 21:331-332.
9) Shugar JK. Use of epinephrine for IFIS prophylaxis. J Cataract Refract Surg 2006;32:1074-1075.
10) Bendel RE, Phillips MB.Preoperative use of atropine to prevent intraoperative floppy iris syndrome in patients taking tamsulosin. J Cataract Refract Surg 2006; 32:1603-1605.
11) Masket S, Belani S. Combined preoperative topical atropine sulfate 1% and intracameral nonpreserved epinephrine hydrochloride 1:4000 for management of intraoperative floppy-iris syndrome. J Cataract Refract Surg 2007; 33:580-582.
12) Colvard DM, Kandavel R. Viscoelastic solutions to challenging surgeries. Rev Ophthalmol 2006; 13:1-3.
13) Takmaz T, Can I.Intraoperative floppy-iris syndrome: do we know everything about it? J Cataract Refract Surg 2007;33:1110-1112.
14) Takmaz T, Can I. Clinical features, complications, and incidence of intraoperative floppy iris syndrome in patients taking tamsulosin. Eur J Ophthalmol 2007;17:909-913.
15) Yaycıoğlu R, Yaycıoğlu O, Gul U, Pelit A, Adıbelli FM, Akova A. The effect of two systemic alpha-1 adrenergic blockers on pupil diameter: a prospective randomized single-blind study. Naunyn- Schmiedeberg’s Arch Pharmacol 2007; 375:199-203.
16) Schwing DA, Asfari NA.: Alpha(1)-adrenergic receptor antagonists and the iris: new mechanistic insights into Floppy Iris Syndrome. Surv Ophthalmol 2006; 51:501-512.
17) Pianka P, Oron Y, Lazar M, Gever O. Nonadrenergic, noncholinergic relaxation of bovine iris sphincter: role of endogeneous nitric oxide. Invest Ophthalmol Vis Sci 2000; 41: 880-886.
18) De la Rosette J, Madersbacher S, Alivizatos G: EAU guidelines on benign prostatic hyperplasia. Eur Urol 2004; 46:547-554.
19) Roehrborn CG, McConnell JD, Barry MJ, et al: AUA guidelines on the management of benign prostatic hyperplasia(BPH). J Urol 2003; 170: 530-547.
20) Leonardini A, Hiebel JB, Guarneri L, Naselsky DP, Poggesi E, Sironi G, et al. Pharmalogical characterization of uroselective alpha1 antagonist rec. 15/2739(SB 216469): role of the alpha 1L adrenoreceptor in tissue selectivity, part 1. J Pharmacol Exp Ther 1997; 281:1272-1293.
21) Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant alpha-1 adrenoreceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995; 288; 201-207.
22) Roehrborn CG, Schwinn DA.: Alpha1-adrenergicibitors receptors and their inhibitors in lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2004; 171: 1029-1035.
23) Cheung CM, Awan MA, Sandramouli S. Prevalence and clinical findings of tamsulosin-associated intraoperative floppy-iris syndrome. J Cataract Refract Surg 2006; 32:1336-1339.
24) Küpeli B, Irklita L, Gürocak S, Tunç L, Kiraç M, Karaoğlan U, Bozkırlı I. Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy? Urology 2004; 64:1111-1115.
25) Lee SW, Liong ML, Yuen KH, Liong YV, Krieger JN. Chronic prostatitis/chronic pelvic pain syndrome: role of alpha blocker therapy. Urol Int 2007; 78:97-105.
26) Sinha D, Arunkalaivanan A. Urethral syndrome: response to alpha-adrenergic blocking agents. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:659-660.
27) Nathan Lawrentschuk and Guy W.Bylsma. Intraoperative ‘floppy-iris’ syndrome and its relationship to tamsulosin: a urologist’s guide. BJU Int 2006; 97:2-4.